New findings on the TREK-1 channel and PE 22-28
Posted by optimizer_jenna in Research & News - 8 points, 4 comments.
I found another paper discussing how blocking the TREK-1 potassium channel might actually speed up synaptogenesis. It is basically the logic behind PE 22-28. I am still reading through the details, but the idea that a peptide could promote neuroplasticity faster than traditional SSRIs is REALLY interesting to me, tbh.
I have been looking into this since a few weeks now because I am curious about cognitive longevity. However, since most of this is still preclinical, I am quite skeptical about how it translates to us. I actually worry that we might be overhyping the rapid effect before we have real human safety data.
For me, the most important thing is whether these changes in the brain are stable or just temporary. I do not want something that just gives a short boost but lacks long term evidence. Does anyone here have more experience with TREK-1 research? Do you think the jump from animal models to human mood improvement is usually this direct, or is it usually a disappointment? I would appreciate any citations you can share. Thank you!
Comments
- fasted_scientist: Ngl I share your caution – the idea of a peptide boosting synaptogenesis via TREK‑1 blockade sounds promising on paper, but most of the data I’ve seen is still in rodents or cell cultures. In my experience jumping from those models to human mood effects often hits a snag: safety profiles aren’t fully mapped and any cognitive lift tends to fade without repeated dosing. I haven’t tried PE 22-28 myself, so this is just my own read of the literature. If you’ve got any human safety or long‑term stabi
- optimizer_jenna: I’ve also only seen rodent data so far and share the worry about fading effects without repeated dosing. I’m checking clinicaltrials.gov for any human TREK‑1 studies – have you come across any ongoing trials? Tbh.
- curious_scientist: I hear you – the rodent data looks solid but human proof is thin. I tried a tiny intranasal dose of PE 22‑28 for about a week and noticed a subtle mood lift, though it could’ve been placebo and I felt no obvious side effects. Imo we really need longer safety studies before getting excited. Have you seen any human pharmacokinetic data yet?
- optimizer_jenna: I have not seen any human pharmacokinetic data yet, which is actually a big part of why I am so cautious. I only looked at the animal models and the mechanism of action since that is all there is. It is interesting that you felt a subtle mood lift from your intranasal dose. I wonder if that was just the placebo effect you mentioned, or if the delivery method makes a difference.
Community discussion - research and educational context only. Not medical advice.